On this day..., page-8

Mark, I would not see a CR unless there was an outstanding opportunity. If so and I concurred with such an opportunity I'd be in there like Flynn.

I would think that SRX could borrow $100m without too much trouble, so a CR would have to be a serious event.

Profit downgrade - well I think it worthwhile to give your SS some 'what if' analysis for various dose sales % increases. I have about 15% pencilled in based on the current SP.

Then it's a case of looking forward and attempting to judge what impact future events will have on dose sales. Clearly +ve trial data would be considered.

Next we have to consider the expansion of marketing / sales (particularly in the US) where the product still has to be 'sold' to new centres, new medcos etc.
Any upgrade to the recommendations from one of the medic bodies would make said sales task an awful lot easier. Especially in the US where the large market is, and provide ammunition for the other markets.

2017 is going to be potentially a huge year for SRX. I've started a SS with the events, those we have been told, and those we have gleaned from various PD data. Happy to take any views as to what should be included, and maybe I'll start a new thread for discussion next week.

Those old rose tinted spectacles, again

Best.